BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

597 related articles for article (PubMed ID: 27585680)

  • 21. Long-term Follow-up Assessing Renal Angiomyolipoma Treatment Patterns, Morbidity, and Mortality: An Observational Study in Tuberous Sclerosis Complex Patients in the Netherlands.
    Eijkemans MJ; van der Wal W; Reijnders LJ; Roes KC; van Waalwijk van Doorn-Khosrovani SB; Pelletier C; Magestro M; Zonnenberg B
    Am J Kidney Dis; 2015 Oct; 66(4):638-45. PubMed ID: 26165440
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Natural history of patients with tuberous sclerosis complex related renal angiomyolipoma.
    Song X; Liu Z; Cappell K; Gregory C; Said Q; Prestifilippo J; Charles H; Hulbert J; Bissler J
    Curr Med Res Opin; 2017 Jul; 33(7):1277-1282. PubMed ID: 28358266
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Review of the Tuberous Sclerosis Renal Guidelines from the 2012 Consensus Conference: Current Data and Future Study.
    Kingswood JC; Bissler JJ; Budde K; Hulbert J; Guay-Woodford L; Sampson JR; Sauter M; Cox J; Patel U; Elmslie F; Anderson C; Zonnenberg BA
    Nephron; 2016; 134(2):51-58. PubMed ID: 27504842
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Renal manifestations of tuberous sclerosis complex.
    Fatihi el M; Khanfri N; Niang A; Ghafel C; Hachim K; Zahiri K; Benghanem MG; Ramdani B; Zaid D
    Ann Med Interne (Paris); 2003 Sep; 154(4):255-8. PubMed ID: 14593316
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sirolimus and tuberous sclerosis-associated renal angiomyolipomas.
    Krischock L; Beach R; Taylor J
    Arch Dis Child; 2010 May; 95(5):391-2. PubMed ID: 20457704
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differentiation of Sporadic Versus Tuberous Sclerosis Complex-Associated Angiomyolipoma.
    Rabenou RA; Charles HW
    AJR Am J Roentgenol; 2015 Aug; 205(2):292-301. PubMed ID: 26204278
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Response to everolimus is seen in TSC-associated SEGAs and angiomyolipomas independent of mutation type and site in TSC1 and TSC2.
    Kwiatkowski DJ; Palmer MR; Jozwiak S; Bissler J; Franz D; Segal S; Chen D; Sampson JR
    Eur J Hum Genet; 2015 Dec; 23(12):1665-72. PubMed ID: 25782670
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Recent advance in tuberous sclerosis-related genes and their expression].
    Liu J; Piao YS; Lu DH
    Zhonghua Bing Li Xue Za Zhi; 2010 Mar; 39(3):210-2. PubMed ID: 20450774
    [No Abstract]   [Full Text] [Related]  

  • 29. Possible prevention of tuberous sclerosis complex lesions.
    Kotulska K; Borkowska J; Jozwiak S
    Pediatrics; 2013 Jul; 132(1):e239-42. PubMed ID: 23733802
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Low-dose rapamycin reduces kidney volume angiomyolipomas and prevents the loss of renal function in a patient with tuberous sclerosis complex.
    Peces R; Peces C; Cuesta-López E; Pérez-Dueñas V; Vega-Cabrera C; Azorín S; Selgas R
    Nephrol Dial Transplant; 2010 Nov; 25(11):3787-91. PubMed ID: 20663789
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Renal tumors in tuberous sclerosis complex.
    Trnka P; Kennedy SE
    Pediatr Nephrol; 2021 Jun; 36(6):1427-1438. PubMed ID: 33006051
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Rapamycin in the treatment of renal diseases associated with tuberous sclerosis complex].
    Dun S; Zou LP; Zhang MN; Wang YY; He W; Chen HM; Hu LY; Chen XQ; Lu Q; Pang LY; Liu LY; Tang LN; Wang B
    Zhonghua Er Ke Za Zhi; 2019 Nov; 57(11):852-856. PubMed ID: 31665839
    [No Abstract]   [Full Text] [Related]  

  • 33. Selective arterial embolization of giant renal tuberous sclerosis.
    De Pasquale V; Natali G; Falappa P; Nappo SG; Salerno A; Caione P
    Indian J Pediatr; 2013 Mar; 80(3):263-5. PubMed ID: 22392265
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Renal phenotypes correlate with genotypes in unrelated individuals with tuberous sclerosis complex in China.
    Luo C; Zhang Y; Zhang YS; Zhang MX; Ning J; Chen MF; Li Y; Qi L; Zu XB; Li YL; Cai Y
    Orphanet J Rare Dis; 2022 Jul; 17(1):288. PubMed ID: 35870981
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical presentations and molecular studies of invasive renal epithelioid angiomyolipoma.
    Chuang CK; Lin HCA; Tasi HY; Lee KH; Kao Y; Chuang FL; Chang YH; Lin PH; Liu CY; Pang ST
    Int Urol Nephrol; 2017 Sep; 49(9):1527-1536. PubMed ID: 28547571
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of mTOR inhibition in the treatment of patients with renal angiomyolipomas.
    Coombs EJ
    J Am Assoc Nurse Pract; 2013 Nov; 25(11):588-96. PubMed ID: 24170533
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tuberous sclerosis complex.
    Hasbani DM; Crino PB
    Handb Clin Neurol; 2018; 148():813-822. PubMed ID: 29478616
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Everolimus improves neuropsychiatric symptoms in a patient with tuberous sclerosis carrying a novel TSC2 mutation.
    Hwang SK; Lee JH; Yang JE; Lim CS; Lee JA; Lee YS; Lee K; Kaang BK
    Mol Brain; 2016 May; 9(1):56. PubMed ID: 27216612
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Everolimus in immunosuppressive treatment after kidney transplantation in a patient with tuberous sclerosis: case report.
    Tarasewicz A; Dębska-Ślizień A; Bułanowski M; Więcek A; Rutkowski B
    Transplant Proc; 2014 Oct; 46(8):2912-5. PubMed ID: 25380949
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Advanced sporadic renal epithelioid angiomyolipoma: case report of an extraordinary response to sirolimus linked to TSC2 mutation.
    Espinosa M; Roldán-Romero JM; Duran I; de Álava E; Apellaniz-Ruiz M; Cascón A; Garrigos C; Robledo M; Rodriguez-Antona C
    BMC Cancer; 2018 May; 18(1):561. PubMed ID: 29764404
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.